Css LLC Il Invests $435,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

CSS LLC IL bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 610 shares of the biopharmaceutical company's stock, valued at approximately $435,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Merit Financial Group LLC raised its holdings in shares of Regeneron Pharmaceuticals by 8.9% in the 4th quarter. Merit Financial Group LLC now owns 868 shares of the biopharmaceutical company's stock valued at $618,000 after purchasing an additional 71 shares during the period. Diversify Advisory Services LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $234,000. Crossmark Global Holdings Inc. lifted its position in Regeneron Pharmaceuticals by 3.6% during the fourth quarter. Crossmark Global Holdings Inc. now owns 2,654 shares of the biopharmaceutical company's stock worth $1,890,000 after acquiring an additional 92 shares during the last quarter. Atomi Financial Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 7.0% during the fourth quarter. Atomi Financial Group Inc. now owns 615 shares of the biopharmaceutical company's stock worth $438,000 after acquiring an additional 40 shares during the period. Finally, Dakota Wealth Management grew its position in shares of Regeneron Pharmaceuticals by 2.9% in the fourth quarter. Dakota Wealth Management now owns 1,366 shares of the biopharmaceutical company's stock valued at $973,000 after purchasing an additional 39 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on REGN. UBS Group dropped their price target on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating for the company in a report on Wednesday, April 30th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research report on Monday, March 31st. Guggenheim lowered their price objective on Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Finally, TD Cowen dropped their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $890.60.

Regeneron Pharmaceuticals Stock Down 0.3%

Shares of NASDAQ:REGN traded down $1.86 during midday trading on Wednesday, hitting $601.40. 330,033 shares of the company's stock were exchanged, compared to its average volume of 799,893. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 12 month low of $520.50 and a 12 month high of $1,211.20. The company has a market cap of $64.93 billion, a PE ratio of 15.71, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The stock has a 50 day moving average price of $589.51 and a 200-day moving average price of $671.75.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter last year, the company earned $9.55 EPS. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.59%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.